Medcell Pharma
Indian Pharmaceutical Exporter · Advanced Antibiotics Specialist · $7.5M Total Trade · DGFT Verified
Medcell Pharma is an Indian pharmaceutical exporter with a total trade value of $7.5M across 6 products in 4 therapeutic categories. Based on 180 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Ceftriaxone ($2.7M), Ofloxacin ($1.9M), Levofloxacin ($1.3M).
Medcell Pharma — Export Portfolio & Destination Treemap
Who is Medcell Pharma? — Company Overview & Market Position
Medcell Pharma Private Limited, established on September 13, 2022, is a private pharmaceutical company headquartered in Gurugram, Haryana, India. The company is registered under the Corporate Identification Number (CIN) U24230HR2022PTC106564. As of March 13, 2025, Medcell Pharma employed 208 professionals. The company's authorized capital is ₹1 crore, with a paid-up capital of ₹1 crore. Medcell Pharma operates in the pharmaceutical manufacturing sector, focusing on drug formulation and development.
The company's mission is to enhance the quality of life through innovative healthcare solutions, emphasizing niche therapeutic areas and preventive care. Medcell Pharma manufactures patented pharmaceutical products and high-end nutraceuticals, combining scientific research with health and wellness to deliver brands that prevent and manage lifestyle-related diseases.
What Does Medcell Pharma Export? — Product Portfolio Analysis
Top Products by Export Value
Medcell Pharma Therapeutic Categories — 4 Specializations
Medcell Pharma operates across 4 therapeutic categories, with Advanced Antibiotics (64.8%), Antibiotics (17.3%), Gastrointestinal (17.3%) representing the largest segments by export value. The portfolio is concentrated — the top 5 products account for 100% of total exports.
Advanced Antibiotics
3 products · 64.8% · $4.9M
Antibiotics
1 products · 17.3% · $1.3M
Gastrointestinal
1 products · 17.3% · $1.3M
Other
1 products · 0.5% · $39.7K
Product Portfolio — Top 6 by Export Value
Medcell Pharma exports 6 pharmaceutical products across 4 therapeutic categories.
| # | Product | Category | Export Value | Shipments | Market Share | Rank |
|---|---|---|---|---|---|---|
| 1 | Ceftriaxone | Advanced Antibiotics | $2.7M | 54 | 0.9% | 5 |
| 2 | Ofloxacin | Advanced Antibiotics | $1.9M | 38 | 0.6% | 13 |
| 3 | Levofloxacin | Antibiotics | $1.3M | 26 | 1.8% | 5 |
| 4 | Ondansetron | Gastrointestinal | $1.3M | 32 | 1.1% | 15 |
| 5 | Amikacin | Advanced Antibiotics | $267.9K | 27 | 1.3% | 13 |
| 6 | Nicotine | Other | $39.7K | 3 | 0.3% | 7 |
Medcell Pharma exports 6 pharmaceutical products across 4 therapeutic categories with a total export value of $7.5M. The top category is Advanced Antibiotics (64.8% of portfolio), followed by Antibiotics (17.3%), indicating a concentrated portfolio with the top 5 products accounting for 99.5% of total export value.
Key Metrics
Top Categories
Top Export Routes
Related Analysis
Medcell Pharma — Corporate Profile & Information
Headquarters, ownership, manufacturing facilities, and key leadership
1Corporate Overview
Medcell Pharma Private Limited, established on September 13, 2022, is a private pharmaceutical company headquartered in Gurugram, Haryana, India. The company is registered under the Corporate Identification Number (CIN) U24230HR2022PTC106564. As of March 13, 2025, Medcell Pharma employed 208 professionals. The company's authorized capital is ₹1 crore, with a paid-up capital of ₹1 crore. Medcell Pharma operates in the pharmaceutical manufacturing sector, focusing on drug formulation and development.
The company's mission is to enhance the quality of life through innovative healthcare solutions, emphasizing niche therapeutic areas and preventive care. Medcell Pharma manufactures patented pharmaceutical products and high-end nutraceuticals, combining scientific research with health and wellness to deliver brands that prevent and manage lifestyle-related diseases.
2Manufacturing Facilities
Medcell Pharma's manufacturing facilities are located in Leiden, Netherlands, and Olsztyn, Poland. The plant in Leiden is accredited by the Ministry of Health (MOH) of approximately 25 countries and is registered with the Medical Evaluation Board (Dutch Authority) and the European Medicines Agency (EMA) as an EU-GMP approved manufacturer. The Olsztyn facility is also EU-GMP certified. These state-of-the-art facilities adhere to stringent quality standards, ensuring the production of high-quality pharmaceutical and nutraceutical products.
3Key Leadership
Medcell Pharma's leadership team comprises directors Gunjan Bhatia, Aditya Bhatia, and Anita Bhatia. Gunjan Bhatia and Aditya Bhatia have been serving as directors since the company's inception on September 13, 2022. Anita Bhatia joined the board on September 1, 2023. The leadership team is committed to driving the company's mission of enhancing quality of life through innovative healthcare solutions.
Where Does Medcell Pharma Export? — Destination Intelligence
Regulated market presence, emerging market penetration, and geographic strategy
1Regulated Markets
Medcell Pharma has established a significant presence in regulated markets, particularly in Europe and the Middle East. The company's manufacturing plants are audited and approved by the Ministry of Health of around 25 countries and are registered with the Medical Evaluation Board (Dutch Authority) and the European Medicines Agency (EMA) as EU-GMP approved manufacturers. This extensive regulatory compliance facilitates market access and underscores the company's commitment to maintaining high-quality standards.
2Emerging Markets
Medcell Pharma has expanded its reach into emerging markets, including Africa, Latin America, and Southeast Asia. The company's products are available in over 40 countries, indicating a broad international footprint. While specific details regarding WHO prequalification are not available, the company's adherence to international quality standards, such as EU-GMP certification, positions it favorably for market access in these regions.
3Geographic Strategy
Medcell Pharma's geographic strategy demonstrates a strong focus on international expansion, particularly in Europe, the Middle East, and emerging markets. The company's manufacturing facilities in the Netherlands and Poland, along with its products available in over 40 countries, reflect a diversified market presence. This diversification mitigates concentration risk and aligns with the company's strategic direction to enhance global reach and market penetration.
Medcell Pharma — Manufacturing & Regulatory Profile
FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record
1FDA Status
Specific details regarding Medcell Pharma's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's manufacturing facilities are accredited by various international authorities, including the Ministry of Health of around 25 countries, the Medical Evaluation Board (Dutch Authority), and the European Medicines Agency (EMA) as EU-GMP approved manufacturers. However, without explicit FDA approvals or registrations, the company's products may not be authorized for sale in the United States.
2WHO & EU GMP
Medcell Pharma's manufacturing facilities are EU-GMP certified, ensuring compliance with European Good Manufacturing Practices. The company's plant in Leiden is also registered with the Medical Evaluation Board (Dutch Authority) and the European Medicines Agency (EMA) as an EU-GMP approved manufacturer. While specific details regarding WHO prequalification are not available, the company's adherence to EU-GMP standards reflects a commitment to maintaining high-quality manufacturing processes.
3CDSCO & Indian Regulatory
Specific details regarding Medcell Pharma's compliance with the Central Drugs Standard Control Organisation (CDSCO) regulations, state drug controller approvals, and export No Objection Certificates (NOCs) are not publicly available. The company's manufacturing facilities are located in the Netherlands and Poland, and it is registered with the Medical Evaluation Board (Dutch Authority) and the European Medicines Agency (EMA) as an EU-GMP approved manufacturer. However, without explicit information on CDSCO approvals, the company's products may not be authorized for sale in India.
4Recent Regulatory Actions
As of March 28, 2026, there are no publicly available records of Form 483 observations, warning letters, or import alerts issued to Medcell Pharma. The company's manufacturing facilities are accredited by various international authorities, including the Ministry of Health of around 25 countries, the Medical Evaluation Board (Dutch Authority), and the European Medicines Agency (EMA) as EU-GMP approved manufacturers. This suggests a strong compliance record with regulatory standards.
Medcell Pharma — Competitive Positioning Among Indian Pharma Exporters
Market share comparison, key differentiators, and strategic analysis
1Competitive Landscape
Medcell Pharma operates in a competitive pharmaceutical industry, with several key players in overlapping therapeutic categories. While specific market share data is not available, the company's focus on niche and specialty products, including food supplements, generic pharmaceuticals, nutraceuticals, sports supplements, herbal natural minerals, male infertility, orthopaedics, gynaecology, and vitamins, positions it uniquely in the market. This strategic focus allows Medcell Pharma to differentiate itself and cater to specific market segments.
2Key Differentiators
Medcell Pharma's key differentiators include its commitment to quality, as evidenced by its EU-GMP certification and adherence to international manufacturing standards. The company's focus on niche and specialty products, such as food supplements, generic pharmaceuticals, nutraceuticals, sports supplements, herbal natural minerals, male infertility, orthopaedics, gynaecology, and vitamins, allows it to address specific therapeutic areas and unmet medical needs. Additionally, Medcell Pharma's manufacturing facilities are audited and approved by the Ministry of Health of around 25 countries, reflecting a broad international recognition of its quality standards.
3Strategic Position
Medcell Pharma's current strategic direction focuses on the production of niche and specialty products, including food supplements, generic pharmaceuticals, nutraceuticals, sports supplements, herbal natural minerals, male infertility, orthopaedics, gynaecology, and vitamins. The company's adherence to international quality standards, such as EU-GMP certification, and its manufacturing facilities audited and approved by the Ministry of Health of around 25 countries, position it favorably in the global market. Looking ahead, Medcell Pharma is well-positioned to expand its product offerings and market presence, leveraging its strengths in quality manufacturing and specialized product development.
Buyer Due Diligence Brief — Evaluating Medcell Pharma as a Supplier
Track record assessment, certifications to verify, and pre-order checks
1Supplier Assessment
Medcell Pharma has demonstrated a strong track record in pharmaceutical manufacturing, with its products available in over 40 countries. The company's manufacturing facilities are accredited by various international authorities, including the Ministry of Health of around 25 countries, the Medical Evaluation Board (Dutch Authority), and the European Medicines Agency (EMA) as EU-GMP approved manufacturers. This extensive regulatory compliance indicates a high level of reliability and consistency in its manufacturing processes.
2Certifications to Verify
Importers should verify the following certifications when considering Medcell Pharma as a supplier:
- EU-GMP Certification: Confirms compliance with European Good Manufacturing Practices.
- WHO-GMP Certification: Indicates adherence to World Health Organization Good Manufacturing Practices.
- FDA Approval: Ensures products are authorized for sale in the United States.
- ISO Certifications: Demonstrate adherence to international quality management standards.
To verify these certifications, importers should request copies of the certificates directly from Medcell Pharma and cross-reference them with the issuing authorities' official records.
3Due Diligence Checklist
When conducting due diligence on Medcell Pharma,
Frequently Asked Questions — Medcell Pharma
How many pharmaceutical products does Medcell Pharma export from India?
Medcell Pharma exports 6 pharmaceutical products across 4 therapeutic categories. The top exports are Ceftriaxone ($2.7M), Ofloxacin ($1.9M), Levofloxacin ($1.3M), Ondansetron ($1.3M), Amikacin ($267.9K). Total export value is $7.5M.
What is Medcell Pharma's total pharmaceutical export value?
Medcell Pharma's total pharmaceutical export value is $7.5M, based on 180 verified shipments recorded in Indian Customs (DGFT) data.
What therapeutic categories does Medcell Pharma cover?
Medcell Pharma exports across 4 therapeutic categories. The largest are Advanced Antibiotics (64.8%, 3 products), Antibiotics (17.3%, 1 products), Gastrointestinal (17.3%, 1 products).
Get Full Medcell Pharma Export Intelligence
Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Official References & Regulatory Resources
Verify manufacturer licensing, GMP certification, and export registration with the agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Matching: Medcell Pharma identified across shipments using name normalization.
- 2.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 3.Market Share: Calculated per product as Medcell Pharma's capped value divided by total Indian exports for that product.
- 4.Shipment Count: Based on 180 individual customs records matching Medcell Pharma.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
6 Products Tracked
4 therapeutic categories
Expert-Reviewed
By pharmaceutical trade specialists
Data Source & Methodology
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.